Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs GMAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–4 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: MRNA 4 – 2 GMAB Matrix Metrics: MRNA 5 – 4 GMAB

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Genmab A/S ADS (GMAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GMAB carries 40.1/100 (SELL) at $50.60 (29.3x Forward P/E, 30.6% operating margin).

  • Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both MRNA (40.3/100 SELL) and GMAB (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs GMAB
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
GMAB NASDAQ
Genmab A/S ADS
Pharmaceutical Preparations
$50.60
-1.46% 1D
Market Cap $31.7B
TTM Revenue $4.30B
Forward P/E 29.3x
Beta / 30D Vol 0.71β · 106% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (22.1% over 20 days), RSI 55
RSI-14: 55.2 · SMA20: $52.77 · SMA50: $42.98

6-Pillar Scorecard Institutional Category Breakdown (MRNA 4 – 2 GMAB)

Columns: Metric · MRNA · GMAB
1. Valuation Multiples MRNA
Forward P/E 23.0x 29.3x
Trailing P/E 23.0x 43.9x
PEG Ratio N/M 4.61x
EV / Revenue 33.1x 7.4x
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +16.1%
Earnings Growth (YoY) -85.1% -14.7%
TTM Revenue (USD) $2.52B $4.30B
Market Cap $80.7B $31.7B
3. Profitability & Quality GMAB
Gross Margin -42.0% 92.7%
Operating Margin -80.8% 30.6%
Net Profit Margin -110.5% 17.0%
Return on Equity (ROE) -34.5% 12.1%
4. Balance Sheet & Cash Flow GMAB
Cash Generation (TTM) -$2.04B $1.36B EBITDA
Cash Flow Margin -81.0% 31.6% EBITDA Mgn
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $10.01 Book/Sh · 12.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 89.6% (52nd %ile) 32.4% (9th %ile)
Put/Call OI Skew 1.05x (Balanced) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 62.1% of Rev ($2.67B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (5) vs GMAB (4)
Institutional Metric MRNA GMAB Criterion Row Edge
Market Capitalization
Scale
$80.7B $31.7B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 43.9x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 29.3x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +16.1% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 30.6% Higher Margin GMAB
Net Profit Margin
Profitability
-110.5% 17.0% Higher Margin GMAB
Return on Equity (ROE)
Capital Efficiency
-34.5% 12.1% Higher ROE GMAB
52-Week Range Position
Momentum
67% ($22–$281) 74% ($24–$60) Stronger Trend GMAB
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.71β · 106% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $4.30B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 92.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 4.61x PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $1.36B EBITDA ($10.01 Book/Sh · 12.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GMAB +30.27 pp
MRNA: -3.77% · GMAB: +26.5%
3M Horizon GMAB +12.84 pp
MRNA: +40.4% · GMAB: +53.24%
6M Horizon MRNA +227.65 pp
MRNA: +315.96% · GMAB: +88.31%
1Y Horizon MRNA +640.93 pp
MRNA: +706.45% · GMAB: +65.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs GMAB. Trailing 12-month operating profitability (MRNA -80.8% vs GMAB 30.6%) and valuation multiples (MRNA 23.0x vs GMAB 29.3x Forward P/E) are benchmarked directly in Pillar 4 below.

MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x
GMAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.30B
Gross Margin92.7%
Op. Margin30.6%
ROE / Fwd P/E12.1% · 29.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GMAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.4%
IV Percentile 9th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GMAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
GMAB Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $31.7B market capitalization and 30.6% operating margin.
OpEx & R&D Reinvestment 62.1% of Rev ($2.67B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs GMAB Key Questions & Quantitative Answers

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over Genmab A/S ADS (GMAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas GMAB carries 40.1/100 (SELL) at $50.60 (29.3x Forward P/E, 30.6% operating margin). Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both MRNA (40.3/100 SELL) and GMAB (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with GMAB at +16.1% YoY revenue growth and -14.7% YoY earnings growth on $4.30B TTM revenue (92.7% gross margin, 30.6% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $4.30B for GMAB. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 62.1% of Rev ($2.67B) (0 disclosures) for GMAB.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas GMAB trades at 29.3x Forward P/E, 43.9x Trailing P/E, 4.61x PEG, and 7.4x EV/Revenue (31.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus GMAB (12.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, GMAB carries 32.4% implied volatility (9th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.